{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:47:27Z","timestamp":1790660847468,"version":"4.1.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"15","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[2015,10,13]]},"abstract":"<jats:p>Over the past decade, personalized medicine has received considerable attention from researchers, drug developers, and regulatory agencies. Personalized medicine includes identifying patients most likely to benefit and those most likely to experience adverse reactions in response to a drug, and tailoring therapy based on pharmacokinetics or pharmacodynamic response, as well. Perhaps most exciting is finding ways to identify likely responders through genetic, proteomic, or other tests, so that only likely responders will be treated. However, less precise methods such as identifying historical, demographic, or other indicators of increased or reduced responsiveness are also important aspects of personalized medicine. The cardiovascular field has not used many genetic or proteomic markers, but has regularly used prognostic variables to identify likely responders. The development of biomarker-based approaches to personalized medicine in cardiovascular disease has been challenging, in part, because most cardiovascular therapies treat acquired syndromes, such as acute coronary syndrome and heart failure, which develop over many decades and represent the end result of several pathophysiological mechanisms. More precise disease classification and greater understanding of individual variations in disease pathology could drive the development of targeted therapeutics. Success in designing clinical trials for personalized medicine will require the selection of patient populations with attributes that can be targeted or that predict outcome, and the use of appropriate enrichment strategies once such attributes are identified. Here, we describe examples of personalized medicine in cardiovascular disease, discuss its impact on clinical trial design, and provide insight into the future of personalized cardiovascular medicine from a regulatory perspective.<\/jats:p>","DOI":"10.1161\/circulationaha.114.009761","type":"journal-article","created":{"date-parts":[[2015,10,13]],"date-time":"2015-10-13T20:48:12Z","timestamp":1444769292000},"page":"1425-1432","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":36,"title":["Personalized Cardiovascular Medicine Today"],"prefix":"10.1161","volume":"132","author":[{"given":"Alison","family":"Blaus","sequence":"first","affiliation":[{"name":"From Office of New Drugs (A.B., M.R., N.S., R.T., E.F.U.) and Office of Clinical Pharmacology (R.M., M.P., R.N.S.), Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajanikanth","family":"Madabushi","sequence":"additional","affiliation":[{"name":"From Office of New Drugs (A.B., M.R., N.S., R.T., E.F.U.) and Office of Clinical Pharmacology (R.M., M.P., R.N.S.), Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pacanowski","sequence":"additional","affiliation":[{"name":"From Office of New Drugs (A.B., M.R., N.S., R.T., E.F.U.) and Office of Clinical Pharmacology (R.M., M.P., R.N.S.), Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Rose","sequence":"additional","affiliation":[{"name":"From Office of New Drugs (A.B., M.R., N.S., R.T., E.F.U.) and Office of Clinical Pharmacology (R.M., M.P., R.N.S.), Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert N.","family":"Schuck","sequence":"additional","affiliation":[{"name":"From Office of New Drugs (A.B., M.R., N.S., R.T., E.F.U.) and Office of Clinical Pharmacology (R.M., M.P., R.N.S.), Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Stockbridge","sequence":"additional","affiliation":[{"name":"From Office of New Drugs (A.B., M.R., N.S., R.T., E.F.U.) and Office of Clinical Pharmacology (R.M., M.P., R.N.S.), Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Temple","sequence":"additional","affiliation":[{"name":"From Office of New Drugs (A.B., M.R., N.S., R.T., E.F.U.) and Office of Clinical Pharmacology (R.M., M.P., R.N.S.), Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellis F.","family":"Unger","sequence":"additional","affiliation":[{"name":"From Office of New Drugs (A.B., M.R., N.S., R.T., E.F.U.) and Office of Clinical Pharmacology (R.M., M.P., R.N.S.), Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.02.012"},{"key":"e_1_3_2_3_2","unstructured":"US Food and Drug Administration. Paving the way for personalized medicine October 2013. http:\/\/www.fda.gov\/downloads\/scienceresearch\/specialtopics\/personalizedmedicine\/ucm372421.pdf. Accessed April 24 2014"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2007.02898.x"},{"key":"e_1_3_2_5_2","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research. Effient (prasugrel) NDA 022307 Clinical Pharmacology and Biopharmaceutics Review May 2008. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/022307s000_ClinPharmR_p1.pdf. Accessed April 23 2015"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011415527"},{"key":"e_1_3_2_8_2","volume-title":"Norpramin (desipramine hydrochloride) [package insert]","year":"2012","unstructured":"Norpramin (desipramine hydrochloride) [package insert]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; 2012."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.111.184895"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.41.1.815"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02775.x"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809171"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1543"},{"key":"e_1_3_2_14_2","volume-title":"Plavix (clopidogrel bisulfate) [package insert]","year":"2013","unstructured":"Plavix (clopidogrel bisulfate) [package insert]. Bridgewater, NJ: Bristol-Myers Squibb\/Sanofi Pharmaceuticals Partnership; 2013."},{"key":"e_1_3_2_15_2","volume-title":"Toprol-XL (metoprolol succinate) [package insert]","year":"2014","unstructured":"Toprol-XL (metoprolol succinate) [package insert]. Wilmington, DE: AstraZeneca; 2014."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044503"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809329"},{"key":"e_1_3_2_18_2","volume-title":"Coumadin (warfarin sodium) [package insert]","year":"2011","unstructured":"Coumadin (warfarin sodium) [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2011."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706043162301"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807646"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198908103210629"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042934"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1071-9164(99)90001-5"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200105313442202"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0509937103"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60319-4"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315878"},{"key":"e_1_3_2_28_2","volume-title":"Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics","author":"US Food and Drug Administration","year":"2010","unstructured":"US Food and Drug Administration. Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics. 2010. http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm201790.pdf. Accessed April 1, 2015."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200933"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.8.790"},{"key":"e_1_3_2_31_2","volume-title":"New drug, antibiotic and biological drug product regulations: Accelerated approval. Proposed Rule","author":"US Food and Drug Administration.","year":"2014","unstructured":"US Food and Drug Administration. New drug, antibiotic and biological drug product regulations: Accelerated approval. Proposed Rule. 2014. http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/00\/backgrd\/3627b2bm.pdf. Accessed April 1, 2015."},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706628"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31253"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.598987"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812173392503"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199111213252103"},{"key":"e_1_3_2_37_2","first-page":"I","article-title":"Effect of flosequinan on survival in chronic heart-failure - preliminary results of the PROFILE Study.","volume":"88","author":"Packer M","year":"1993","unstructured":"Packer M, Rouleau J, Swedberg K, Pit B, Fisher L, lepper M. Effect of flosequinan on survival in chronic heart-failure - preliminary results of the PROFILE Study. Circulation. 1993;88:I\u2013301.","journal-title":"Circulation"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/4.9.1603"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/376683a0"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.284427"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806182"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08089-3"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000437913.98912.1d"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCULATIONAHA.114.009761","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T06:52:29Z","timestamp":1715583149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.114.009761"}},"subtitle":["A Food and Drug Administration\/Center for Drug Evaluation and Research Perspective"],"short-title":[],"issued":{"date-parts":[[2015,10,13]]},"references-count":42,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2015,10,13]]}},"alternative-id":["10.1161\/CIRCULATIONAHA.114.009761"],"URL":"https:\/\/doi.org\/10.1161\/circulationaha.114.009761","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,13]]},"assertion":[{"value":"2015-10-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}